News IPO Sai Parenteral and Hella Infra Market Receive Sebi Approval for Initial Public OfferingsSai Parenteral and Hella Infra Market Receive Sebi Approval for Initial Public Offerings
Sai Parenteral Limited and Hella Infra Market have received Sebi approval for their IPOs. Sai Parenteral's offering includes a ₹285 crore fresh issue and OFS of 35,00,000 shares, with proceeds allocated for capacity expansion, R&D centre establishment, debt repayment, and subsidiary investment. The pharmaceutical company operates across multiple therapeutic segments and began exports in fiscal 2023.
*this image is generated using AI for illustrative purposes only.
Sai Parenteral Limited and Hella Infra Market have secured final regulatory approval from the Securities and Exchange Board of India (Sebi) for their initial public offerings, marking significant milestones for both companies in accessing public capital markets.
Sai Parenteral IPO Structure
Telangana-based Sai Parenteral filed its draft papers with Sebi on 30 September 2025. The company's public offering comprises two components: a fresh issue worth ₹285 crore and an offer-for-sale of up to 35,00,000 shares.
| Component | Details |
|---|---|
| Fresh Issue | ₹285 crore |
| Offer-for-Sale | Up to 35,00,000 shares |
| Filing Date | 30 September 2025 |
The offer-for-sale includes shares being divested by multiple investors including Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Sreelekha Ganta, Padma Guntupalli, Vijay Gondi, Ideas and Journeys Private Limited, Bhautik Mukund Shah and Nilesh Pravinchandra Doshi.
Fund Utilization Strategy
Sai Parenteral has outlined a comprehensive plan for deploying the IPO proceeds across multiple strategic initiatives:
| Purpose | Amount (₹ crore) |
|---|---|
| Capacity expansion and manufacturing facility upgrades | Over 100 |
| New R&D centre establishment | 18 |
| Debt repayment/prepayment | 20 |
| Working capital requirements | 33.3 |
| Investment in Singapore subsidiary | 36 |
| General corporate purposes | Balance amount |
The company plans to invest ₹36 crore in its wholly owned subsidiary, Sai Parenteral's Pte Limited (Singapore), related to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
Company Profile and Operations
Sai Parenteral operates as a pharmaceutical formulation company specializing in research, development, and manufacturing. The company's business model encompasses branded generic formulations and contract development and manufacturing organisation (CDMO) products and services for both domestic and international markets.
The company's product portfolio spans multiple therapeutic segments:
- Cardiovascular treatments
- Neuropsychiatry medications
- Anti-diabetic formulations
- Respiratory health products
- Antibiotics
- Gastroenterology solutions
- Vitamins, minerals and supplements (VMS)
- Analgesics
- Dermatology products
Manufacturing Capabilities and Market Reach
Sai Parenteral offers various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. In the injectables segment, the company focuses on sterile manufacturing for critical care and penicillin-based therapies, providing delivery systems such as dry powder injections, pre-filled syringes, ampoules, and vials.
The company serves diverse customer segments including central and state government agencies, pharmaceutical companies, and public and private hospitals. Following the acquisition of two manufacturing facilities in Hyderabad, Telangana, Sai Parenteral began export activities in the 2023 fiscal year, supplying products to regulated and semi-regulated markets across Australia, New Zealand, Southeast Asia, the Middle East, and Africa through distributors.
Hella Infra Market Development
Hella Infra Market has also received Sebi approval for its IPO, though the company filed its draft papers through a confidential route. Consequently, specific details regarding the offering structure, fund utilization plans, and company operations have not been made public at this time.
19
